A phase 2 liver trial where the add-on drug didn't help — and the base drug quietly did
Read the Sunday Brief →

Study wrapper · #743

Insights into the Biomarker Potential of Humanin and Mots-c Expression and Telomere Length in Alzheimer's Disease.

Rodríguez-Esparragón F, Cazorla-Rivero SE, Torrealba E, et al. International journal of molecular sciences. 2025.
MixedCase-controlMentions: MOTS-c

Editor's note

This case-control study evaluated humanin and MOTS-c as potential Alzheimer's biomarkers, comparing patients with Alzheimer's, mild cognitive impairment, and subjective cognitive decline controls. Researchers found that blood/plasma transcript (gene-expression) levels of both peptides were reduced in Alzheimer's, while plasma protein concentrations did not discriminate Alzheimer's from mild cognitive impairment, an important discordance between mRNA and protein. This is observational and cross-sectional; it identifies associations, not causes, and the protein-level null tempers enthusiasm. It fits the broader pattern that MOTS-c tends to decline with age and neurodegeneration, but the mixed transcript-versus-protein signal means any biomarker role is preliminary. Publishable as a directly relevant human dataset, weighted as early and internally mixed.

Plain-language abstract

Researchers investigated whether two mitochondria-derived peptides, humanin and MOTS-c, could serve as early markers of Alzheimer's disease. They compared people with Alzheimer's, people with mild cognitive impairment (a possible early stage), and controls with only subjective memory concerns. They measured both the gene-activity levels (how much the peptides' genes were being read) and the actual protein amounts in blood. The gene-activity levels of both peptides were lower in Alzheimer's, but the protein levels in plasma did not clearly separate Alzheimer's from mild cognitive impairment, an important mismatch between the two measures. Lab tests of RNA stability suggested the two peptides' messages degrade at different rates. Because this study simply compared groups at one time, it cannot show cause and effect, and the protein results were not distinguishing. It fits the general finding that MOTS-c tends to fall with age and brain disease, but any role as an Alzheimer's test remains early and unsettled.